Medication safety and combined medication in patients with type 2 diabetes mellitus

doi:10.19803/j.1672-8629.2022.03.18

Abstract

Abstract: Objective To investigate the current incidence of adverse drug reactions (ADR) and combined drug regimens for patients with type 2 diabetes mellitus (T2DM). Methods All the ADR reports of T2DM patients in Shaanxi Province collected between 2015 and 2019 were selected to analyze the basic data, clinical manifestations and influencing factors of ADR, and the combined use of drugs. Results A total of 2 050 cases of ADR related to T2DM patients in Shaanxi Province were collected, including damage to the gastrointestinal system, metabolic and nutritional disorders and damage to the skin and its accessories. Femininity, old age and combined drug use were the common causes of ADR, and combined drug use with metformin accounted for the highest proportion of all cases of combined drug use. Conclusion Clinicians should focus their attention on high-risk groups of ADR, including women, elderly patients and users of multiple drug combinations, and select the proper combination of drugs.

Key words: type 2 diabetes mellitus, hypoglycemic drugs, adverse drug reaction, drug combination

CLC Number:

R969.3

XIANG Yufang, SUN Hui, CHEN Yue, WANG Ningsheng, LUO Shishu, ZHANG Zhi, FENG Bianling. Medication safety and combined medication in patients with type 2 diabetes mellitus[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 313-316.

References

[1] World Health Organization. The top 10 causes of death[EB/OL]. (2020-01-01) [2020-05-01]. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
[2] World Health Organization. Media centre: diabetes[EB/OL]. (2020-02-03) [2020-03-23]. http://www.who.int/en/news-room/fact-sheets/detail/diabetes.
[3] International Diabetes Federation. IDF diabetes atlas 9th edition2019[EB/OL]. (2020-03-01) [2020-04-13].https://diabetesatlas.org/en/.
[4 International Diabetes Federation. Demographic and geographic outline[EB/OL]. (2019-04-11) [2020-04-10]. https://diabetesatlas.org/en/sections/demographic-and-geographic-outline.html.
[5] MORITA Y, MURAYAMA H, ODAWARA M, et al.Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database[J]. Diabetol Metab Syndr, 2019, 11(1): 11-21.
[6] XU Y, WANG L, HE J, et al.Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-959.
[7] WANG YZ, CHEN XY, XIAO T, et al.Investigation and analysis of oral drug therapy mode in type 2 diabetes outpatients in big cities of China[J]. Chinese Journal of Disease Control(中华疾病控制杂志), 2018, 22(3): 222-225.
[8] ZHAO H, XU HM, XU JY.Analysis of 1447 cases of adverse reactions to oral anti-diabetes drugs[J]. Chinese Journal of Pharma-covigilance(中国药物警戒), 2012, 9(12): 737-740.
[9] Chinese guidelines for the prevention and treatment oftype 2 diabetes (2017 edition)[J]. Chinese Journal of Practical Internal Medicine(中国实用内科杂志), 2018, 38(4): 292-344.
[10] SHAN QM.New advances in the clinical treatment of type 2 diabetes[J]. Medical Equipment(医疗装备), 2019, 32(24): 203-204.
[11] YU YH.A Brief analysis of the action characteristics and mechanism of several oral hypoglycemic drugs[J]. Chinese Medical Guide(中国医药指南), 2014, 12(19): 378-379.
[12] SHI HB, CAI Q.Review of clinical adverse reactions of hypoglycemic agents[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2013, 10(3): 159-162.
[13] BROŽ J, URBANOVÁ J.A general view of epidemiology of hypoglycemia in type 1 and type 2 diabetes mellitus[J]. Vnitr Lek, 2019, 65(4):289-294.
[14] TANG L, WANG CC, PENG Y, et al.Research progress of adverse reaction signal detection in combination with drug use[J]. Huaxi Medical Science(华西医学), 2015, 30(3): 585-588.
[15] TANG WL, WANG YM, DU WM, et al.An analysis of adverse reactions of antidiabetic drugs in China for 42 years[J]. Chinese Journal of New Drugs and Clinical Medicine(中国新药与临床杂志), 2002(12): 753-758.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[10]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[11]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[12]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[13]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[14]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[15]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.